At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APRE Aprea Therapeutics, Inc.
Not Yet Opened 02-05 16:00:00 EST
0.6244
-0.0456
-6.81%
盘后0.6000
-0.0244-3.91%
19:57 EST
High0.6700Low0.5996Vol408.60K
Open0.6512D1 Closing0.6700Amplitude10.51%
Mkt Cap4.37MTradable Cap2.85MTotal Shares6.99M
T/O256.40KT/O Rate8.96%Tradable Shares4.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Aprea Therapeutics Names Eugene Kennedy as Chief Medical Advisor
Reuters  ·  02-04 21:30
Aprea Therapeutics Names Eugene Kennedy as Chief Medical Advisor
Aprea Therapeutics Inc. President and CEO Gilad Oren Reports Acquisition of Common Shares
Reuters  ·  02-03
Aprea Therapeutics Inc. President and CEO Gilad Oren Reports Acquisition of Common Shares
Aprea Therapeutics CFO John P. Hamill Acquires Common Shares
Reuters  ·  02-03
Aprea Therapeutics CFO John P. Hamill Acquires Common Shares
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:52 AM
Reuters  ·  01-31
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:52 AM
Aprea Therapeutics prices 6.29M shares at 89c in private placement
TIPRANKS  ·  01-29
Aprea Therapeutics prices 6.29M shares at 89c in private placement
Aprea Therapeutics announces early PoC data in ACESOT-1051 trial
TIPRANKS  ·  01-29
Aprea Therapeutics announces early PoC data in ACESOT-1051 trial
Aprea Therapeutics Reports Early Proof-of-Concept for WEE1 Inhibitor APR-1051 in Solid Tumors
Reuters  ·  01-29
Aprea Therapeutics Reports Early Proof-of-Concept for WEE1 Inhibitor APR-1051 in Solid Tumors
Aprea Therapeutics Inc - 50% Reduction in Lesion, 90% Decrease in CA-125 in Patient
THOMSON REUTERS  ·  01-29
Aprea Therapeutics Inc - 50% Reduction in Lesion, 90% Decrease in CA-125 in Patient
Aprea Therapeutics Announces Early Clinical Proof-of-Concept in the Ongoing Acesot-1051 Dose-Escalation Trial Evaluating Wee1 Inhibitor Apr-1051, Including Partial Response Observed on First Scan
THOMSON REUTERS  ·  01-29
Aprea Therapeutics Announces Early Clinical Proof-of-Concept in the Ongoing Acesot-1051 Dose-Escalation Trial Evaluating Wee1 Inhibitor Apr-1051, Including Partial Response Observed on First Scan
Aprea Therapeutics Inc - Unconfirmed Partial Response at 150 Mg Dose
THOMSON REUTERS  ·  01-29
Aprea Therapeutics Inc - Unconfirmed Partial Response at 150 Mg Dose
Aprea Therapeutics Inc: Additional Updates in First Half of 2026 and Completing Dose Escalation Later in Year
THOMSON REUTERS  ·  01-29
Aprea Therapeutics Inc: Additional Updates in First Half of 2026 and Completing Dose Escalation Later in Year
Aprea Therapeutics Announces $5.6 Million Private Placement Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  01-29
Aprea Therapeutics Announces $5.6 Million Private Placement Priced at-the-Market Under Nasdaq Rules
Aprea Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price
Reuters  ·  01-26
Aprea Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price
U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart
Reuters  ·  2025-12-22
U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart
Aprea Therapeutics Inc - Files Prospectus for Resale of 5.5 Mln Shares by the Selling Stockholders - SEC Filing
THOMSON REUTERS  ·  2025-12-20
Aprea Therapeutics Inc - Files Prospectus for Resale of 5.5 Mln Shares by the Selling Stockholders - SEC Filing
Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $20
THOMSON REUTERS  ·  2025-12-19
Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $20
BRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026
Reuters  ·  2025-12-18
BRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026
Aprea Therapeutics Inc - Pauses Enrollment in Aboya-119 Study Monotherapy Arms
THOMSON REUTERS  ·  2025-12-18
Aprea Therapeutics Inc - Pauses Enrollment in Aboya-119 Study Monotherapy Arms
Director Marc Duey Reports Acquisition of Common Shares in Aprea Therapeutics Inc
Reuters  ·  2025-12-11
Director Marc Duey Reports Acquisition of Common Shares in Aprea Therapeutics Inc
Aprea Therapeutics CFO John P. Hamill Reports Acquisition of Common Shares
Reuters  ·  2025-12-11
Aprea Therapeutics CFO John P. Hamill Reports Acquisition of Common Shares

Introduction

Company Name.
Aprea Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Issue price:
--